PubMed Health⌕ Search

PubMed · 10212345

White-coat hypertension: not guilty when correctly defined.

Abstract

The coexistence of persistently high office blood pressure with normal blood pressujre outside the medical setting is often referred to as 'white-coat', 'office' or 'isolated clinic' hypertension. The definition of normal blood pressure outside the medical setting is controversial. In our experience, not only the prevalence of white-coat hypertension, but also left ventricular mass measured echocardiographically and the prevalence of left ventricular hypertrophy in this condition markedly vary on going from more restrictive (lower) to more liberal (higher) limits of ambulatory blood pressure normalcy over quite a narrow range. In a prospective study, cardiovascular morbidities of healthy normotensive controls and subjects with white-coat hypertension did not differ. A more recent analysis of our database supports the use of qujite a restrictive definition of white-coat hypertension (average daytime blood pressure < 130/80 mmHg) in order to identify the minority of subjects who have a low risk of cardiovascular morbid events during the subsequent years. A recent document published by the American Society of Hypertension suggests that slightly higher upper limits of ambulatory blood pressure normalcy (i.e. average daytime blood pressure < 135 mmHg systolic and 85 mmHg diastolic) should be used. In a follow-up study by our group, 37% of subjects with white-coat hypertension spontaneously evolved into cases of ambulatory hypertension, with accompanying increases in left ventricular mass. In that study, the probability of a subject developing ambulatory hypertension increased with the baseline values of ambulatory blood pressure and it was quite low (20%) for those with daytime blood pressures below 130/80 mmHg. In two recent controlled studies, the rate of development of ambulatory hypertension over time for untreated subjects did not differ between the normotensive control group and the group with white-coat hypertension. A final answer regarding the clinical significance of white-coat hypertension will come from very large surveys of the natural history of this condition in the long term. For now, we suggest a verdict of innocence for white-coat hypertension when low values of daytime ambulatory blood pressure (i.e. < 130/80 mmHg) and absence of organ lesions and other risk factors coexist.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Verdecchia, G Schillaci, C Borgioni, A Ciucci, C Porcellati. 1998. White-coat hypertension: not guilty when correctly defined.. https://pubmed.ncbi.nlm.nih.gov/10212345/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗